Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$24.10
+1.25 (+5.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-175.7M · quality 63.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-22.8%
↓Gross Margin
40.1%
↓Debt/Equity
0.66
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.2%
FCF CAGR
—
FCF margin
-19.6%
FCF / Net income
0.96x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $898.3M · net income $-183.2M · FCF $-175.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $898.3M | $898.3M | $861.9M | $771.6M | $671.8M |
| Net Income | $-183.2M | $-183.2M | $-98.7M | $-91.0M | $-33.8M |
| EBITDA | $-92.9M | $-92.9M | $-8.4M | $-29.4M | $4.4M |
| EPS | — | — | -2.14 | -1.98 | -0.74 |
| Gross Margin | 40.1% | 40.1% | 44.3% | 39.8% | 42.7% |
| Operating Margin | -19.4% | -19.4% | -9.1% | -10.4% | -4.9% |
| Net Margin | -20.4% | -20.4% | -11.5% | -11.8% | -5.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.66 | 0.66 | 0.44 | 0.34 | 0.31 |
| Current Ratio | 1.78 | 1.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-175.7M | $-175.7M | $-356.9M | $-170.4M | $-2.3M |
| Returns | |||||
| ROE | -22.8% | -22.8% | -10.0% | -8.2% | -2.8% |
| Valuation | |||||
| EV/EBITDA | — | — | — | — | 177.26 |
| P/B | 1.38 | 1.38 | 1.49 | 1.20 | 1.08 |
| Growth & Yield | |||||
| Revenue Growth | 4.2% | 4.2% | 11.7% | 14.9% | — |
| EPS Growth | — | — | -8.1% | -167.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.14 → n/d
Residual
-4.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.